March 21, 2001
Genzyme General and Pharming Report Publication of Study Results for Pompe Disease Therapy
Excerpt From Press Release-March 20, 2001 CAMBRIDGE, MA and LEIDEN,the Netherlands—Genzyme General (Nasdaq: GENZ), a division of Genzyme Corp., and
The following is a transcript of a telephone interview conducted for the IPA(International Pompe Association) by Kevin O’Donnell of the
October 6, 2000
Genzyme General and Pharming Group Report Results From First Two Clinical Trials for Pompe Disease
Excerpt From Press Release—October 5, 2000 Genzyme General and Pharming Group N.V., announced today that results from the first two
Chen focused on the phase I/II trials underway at Duke with 3 IIa infants. Average age at diagnosis is 5
October 1, 2000
Statement from Genzyme and Pharming
Genzyme Corporation and it’s development partner, Pharming N.V., are committed to providing an effective and practical therapy for Pompe disease